Recent Company News

• 06:41 PM ET Apr 16, 2026
  

  Street Takeaways - Daiichi Sankyo sale of Daiichi Sankyo Healthcare to Suntory HD for ¥246.50B (¥2889.0000, 0)

• 02:38 AM ET Apr 15, 2026
  

  Daiichi Sankyo confirms sale of DAIICHI SANKYO HEALTHCARE to Suntory HD for ¥246.50B (¥2832.0000, 0)

• 12:19 AM ET Apr 15, 2026
  

  Suntory Holdings to buy Daiichi Sankyo's OTC unit for ~¥200B - Nikkei (¥2817.0000, +83)

• 07:02 AM ET Apr 13, 2026
  

  Ifinatamab deruxtecan granted priority review in the U.S. for adult patients with previously treated extensive-stage small cell lung cancer who experienced disease progression on or after platinum-based chemotherapy ($121.42, 0.00)

• 09:35 PM ET Apr 07, 2026
  

  StreetAccount Sector Summary - China Healthcare March Recap

• 08:05 AM ET Apr 01, 2026
  

  Nuvation Bio announces acquisition of Japan rights to safusidenib from Daiichi Sankyo ($4.29, 0.00)

• 02:37 AM ET Mar 30, 2026
  

  Sumitomo Pharma submits partial change application in Japan to add pediatric dosage and administration for LATUDA (¥2107.0000, 0)

• 04:36 AM ET Mar 27, 2026
  

  China's NMPA conditionally approves Daiichi Sankyo's ENHERTU followed by THP for HER2 positive stage 2 (high risk) or stage 3 breast cancer (¥2930.0000, 0)

• 10:57 PM ET Mar 25, 2026
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 11:06 PM ET Mar 24, 2026
  

  Daiichi Sankyo completes up-to-¥200.0B on-market buyback (¥3002.0000, -8)